Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001415889-16-004781
Filing Date
2016-02-16
Accepted
2016-02-16 16:04:28
Documents
64
Period of Report
2015-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q vsta10q_dec312015.htm 10-Q 1765528
2 FORM OF WARRANT EXCHANGE AGREEMENT ex10-2.htm EX-10.2 58347
3 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER REQUIRED BY RULE 13A-14(A) UNDE ex31-1.htm EX-31.1 9380
4 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER REQUIRED BY RULE 13A-14(A) UNDE ex31-2.htm EX-31.2 10227
5 CERTIFICATION OF THE PRINCIPAL EXECUTIVE AND FINANCIAL OFFICERS REQUIRED BY RULE ex32.htm EX-32 7842
  Complete submission text file 0001415889-16-004781.txt   6145887

Data Files

Seq Description Document Type Size
6 vsta-20151231.xml EX-101.INS 1148313
7 vsta-20151231.xsd EX-101.SCH 49019
8 vsta-20151231_cal.xml EX-101.CAL 48102
9 vsta-20151231_def.xml EX-101.DEF 287422
10 vsta-20151231_lab.xml EX-101.LAB 284083
11 vsta-20151231_pre.xml EX-101.PRE 330583
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-244-9990
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

EIN.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-54014 | Film No.: 161427937
SIC: 2834 Pharmaceutical Preparations